Fairtility Closes $15M Series A Funding
- Fairtility, a Tel Aviv Israel-based transparent AI innovator powering in vitro fertilization (IVF), closed a $15 million Series A funding round
- The round, which brings total funding to $18.5m to date, was led by Gurnet Point Capital, and included Nacre Capital and additional investors
- The company intends to use the funds to advance clinical research with fertility clinics and academic institutions globally, regulatory approval processes
- The company provides an Embryo Quality Assessment Assistant that transforms AI-decision-making in IVF into a transparent process for both clinicians and patients
- CHLOE EQ™ (Cultivating Human Life through Optimal Embryos) provides visibility into the biological data that informs the system’s embryo assessment conclusions
